{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T13:30:51Z","timestamp":1784813451046,"version":"3.55.0"},"reference-count":16,"publisher":"Scientific Scholar","issue":"5&6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,5]]},"abstract":"<jats:sec>\n            <jats:title>Background &amp; objectives:<\/jats:title>\n            <jats:p>During the COVID-19 pandemic it was important to assess the antibody profile in individuals vaccinated with Covaxin (BBV152) and Covishield (ChAdOx1 nCoV-19) with both 28 and 84 days gaps between two doses, those infected with SARS-CoV-2 and post-COVID-19-infected individuals vaccinated with only one dose of either of the vaccines. The present study was aimed to assess these objectives.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Fifty real time reverse transcription\u2013polymerase chain reaction (qRT-PCR)-confirmed COVID-19-infected individuals, along with 90 COVID-19-na\u00efve (BBV152 and ChAdOx1 nCov-19)\u2013vaccinated individuals, were included in the study. Individuals who received a single dose of either vaccine with a confirmed past diagnosis of SARS-CoV-2 infection (n=15) were also included. Blood samples were collected strictly between the 4<jats:sup>th<\/jats:sup> and 5<jats:sup>th<\/jats:sup> wk after development of symptoms for SARS-CoV-2 infected individuals and after the first\/second vaccination dose. Antibody profile assessment was done using whole-virus, spike-receptor binding domain (RBD) and nucleocapsid-specific ELISA kits along with neutralizing antibody kit.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>There was an overall 97.7 per cent seropositivity rate in vaccinated individuals, and a strong correlation (<jats:italic toggle=\"yes\">R<\/jats:italic>\n                                 <jats:sup>2<\/jats:sup>=0.8, <jats:italic toggle=\"yes\">P<\/jats:italic>&lt;0.001) between neutralizing and spike-RBD antibodies. Among individuals who received two standard doses of ChAdOx1 nCoV-19 vaccine, the spike antibody levels developed were of higher titre with a longer prime boost interval than in those with shorter intervals (<jats:italic toggle=\"yes\">P<\/jats:italic>&lt;0.01). Individuals vaccinated with two doses as well as only one dose post-SARS-CoV-2 infection had high neutralizing and spike-specific antibodies.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interpretation &amp; conclusions:<\/jats:title>\n            <jats:p>High neutralizing and spike-specific antibodies were developed in individuals vaccinated only with one dose of either vaccine post-SARS-CoV-2 infection. With the main priority being vaccinating majority of the population in our country, single-dose administration to such individuals would be a sensible way to make the most of the limited supplies. Furthermore, neutralizing antibody levels observed in COVID-19-na\u00efve vaccinees imply the need for booster vaccination.<\/jats:p>\n          <\/jats:sec>","DOI":"10.4103\/ijmr.ijmr_3330_21","type":"journal-article","created":{"date-parts":[[2022,9,18]],"date-time":"2022-09-18T15:17:58Z","timestamp":1663514278000},"page":"538-545","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Antibody profile in post-vaccinated &amp; SARS-CoV-2 infected individuals"],"prefix":"10.25259","volume":"155","author":[{"given":"Rucha","family":"Patil","sequence":"first","affiliation":[{"name":"Department of Haemostasis and Thrombosis, ICMR-National Institute of Immunohaematology, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharda","family":"Shanbhag","sequence":"additional","affiliation":[{"name":"Department of Haemostasis and Thrombosis, ICMR-National Institute of Immunohaematology, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aruna","family":"Shankarkumar","sequence":"additional","affiliation":[{"name":"Department of Haemostasis and Thrombosis, ICMR-National Institute of Immunohaematology, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manisha","family":"Madkaikar","sequence":"additional","affiliation":[{"name":"Department of Haemostasis and Thrombosis, ICMR-National Institute of Immunohaematology, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10894","published-online":{"date-parts":[[2022,10,28]]},"reference":[{"key":"B1-20241212","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S0140-6736(21)00432-3","article-title":"Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine:A pooled analysis of four randomised trials","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"B2-20241212","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2:An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"B4-20241212","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S1473-3099(20)30942-7","article-title":"Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152:A double-blind, randomised, phase 1 trial","volume":"21","author":"Ella","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"B5-20241212","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/S1473-3099(21)00070-0","article-title":"Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152:Interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial","volume":"21","author":"Ella","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"B6-20241212","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","article-title":"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2:A preliminary report of a phase \u00bd, single-blind, randomised controlled trial","volume":"396","author":"Folegatti","year":"2020","journal-title":"Lancet"},{"key":"B7-20241212","doi-asserted-by":"crossref","first-page":"6492","DOI":"10.1016\/j.vaccine.2021.09.055","article-title":"Antibody response after first and second-dose of ChAdOx1-nCOV (Covishield\u2122\u00ae) and BBV-152 (Covaxin\u2122\u00ae) amongst health care workers in India:The final results of cross-sectional coronavirus vaccine-induced antibody titre (COVAT) study","volume":"39","author":"Singh","year":"2021","journal-title":"Vaccine"},{"key":"B8-20241212","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1111\/trf.16401","article-title":"Exponential increase in neutralizing and spike specific antibodies following vaccination of COVID-19 convalescent plasma donors","volume":"61","author":"Vickers","year":"2021","journal-title":"Transfusion"},{"key":"B9-20241212","doi-asserted-by":"crossref","first-page":"e171","DOI":"10.1016\/S2666-5247(21)00060-4","article-title":"Convalescent plasma from people vaccinated after COVID-19 infection","volume":"2","author":"Jabal","year":"2021","journal-title":"Lancet Microbe"},{"key":"B10-20241212","first-page":"2100096","article-title":"Impact of age, ethnicity, sex and prior infection status on immunogenicity following a single dose of the BNT162b2 mRNA COVID-19 vaccine:Real-world evidence from healthcare workers, Israel, December 2020 to January 2021","volume":"26","author":"Abu","year":"2021","journal-title":"Euro Surveill"},{"key":"B11-20241212","article-title":"Antibody responses boosted in seropositive healthcare workers after single dose of SARS-CoV-2 mRNA vaccine","author":"Bradley","year":"2021","journal-title":"medRxiv"},{"key":"B12-20241212","article-title":"Robust spike antibody responses and increased reactogenicity in seropositive individuals after a single dose of SARS-CoV-2 mRNA vaccine","author":"Krammer","year":"2021","journal-title":"medRxiv"},{"key":"B13-20241212","article-title":"Single dose vaccination in healthcare workers previously infected with SARS-CoV-2","author":"Saadat","year":"2021","journal-title":"medRxiv"},{"key":"B14-20241212","doi-asserted-by":"crossref","first-page":"671","DOI":"10.4103\/ijmr.IJMR_2066_21","article-title":"Antibody responses to the BBV152 vaccine in individuals previously infected with SARS-CoV-2:A pilot study","volume":"153","author":"Kumar","year":"2021","journal-title":"Indian J Med Res"},{"key":"B15-20241212","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/s41586-021-03696-9","article-title":"Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection","volume":"595","author":"Wang","year":"2021","journal-title":"Nature"},{"key":"B16-20241212","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.ijid.2021.05.034","article-title":"Immunological memory and neutralizing activity to a single dose of COVID-19 vaccine in previously infected individuals","volume":"108","author":"Sasikala","year":"2021","journal-title":"Int J Infect Dis"},{"key":"B17-20241212","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1002\/jmv.27590","article-title":"Booster vaccination strategy:Necessity, immunization objectives, immunization strategy, and safety","volume":"94","author":"Meng","year":"2022","journal-title":"J Med Virol"}],"container-title":["Indian Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.4103\/ijmr.ijmr_3330_21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T23:05:06Z","timestamp":1751497506000},"score":1,"resource":{"primary":{"URL":"https:\/\/ijmr.org.in\/antibody-profile-in-post-vaccinated-sars-cov-2-infected-individuals\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":16,"journal-issue":{"issue":"5&6","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.4103\/ijmr.ijmr_3330_21","relation":{},"ISSN":["0971-5916","0975-9174"],"issn-type":[{"value":"0971-5916","type":"print"},{"value":"0975-9174","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"2021-11-16","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}}]}}